Publications

An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma

Splice-switch oligonucleotide-based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors

Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study

IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory ​Syndrome Coronavirus 2 (SARS-CoV-2)

Artificial intelligence in cancer therapy

Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma

Harnessing Artificial Intelligence to Optimize Long‐Term Maintenance Dosing for Antiretroviral‐Naive Adults with HIV‐1 Infection

Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine

Artificial Intelligence: Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient ​Using CURATE.AI, an Artificial Intelligence Platform